Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
- Status
- COMPLETED
- Phase
- PHASE3
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
- Status
- COMPLETED
- Phase
- PHASE3
Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy Study for Patients With Stage IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
- Status
- COMPLETED
- Phase
- PHASE1